Diagnostic Approach and Management of Exocrine Pancreatic Insufficiency

Understanding the Diagnostic Approach

The American Gastroenterological Association recommends that Creon (pancreatic enzyme replacement therapy) should be prescribed based on clinical evidence of exocrine pancreatic insufficiency (EPI), not specific lab values, as the diagnosis is primarily clinical and functional rather than laboratory-based 1, 2
Clinical symptoms of maldigestion, such as steatorrhea, weight loss, and malnutrition, are key indicators for prescribing pancreatic enzyme replacement therapy 1, 2
Nutritional status markers, including body mass index, muscle mass, and fat-soluble vitamin deficiencies, support the diagnosis of EPI 1, 2
Underlying pancreatic disease confirmed by imaging and/or laboratory tests is essential for the diagnosis of EPI 1, 3

For acute pancreatitis, serum lipase ≥3 times upper limit of normal is the preferred diagnostic test, while serum amylase ≥3 times upper limit of normal is less specific but still useful 4, 3
Triglycerides >1000 mg/dL (>11.3 mmol/L) indicates hypertriglyceridemia-induced pancreatitis 4, 3
Fat-soluble vitamin levels, including vitamins A, D, E, and K, are essential for assessing malabsorption in EPI 1, 2

Baseline measurements that support starting Creon include low body mass index, fat-soluble vitamin deficiencies, low albumin or prealbumin, and reduced muscle mass 1, 2, 5, 3

Improvement in fat-soluble vitamin levels, weight gain, and improved BMI are indicators of successful treatment with Creon 1, 2
Normalization of albumin/prealbumin is also a marker of successful treatment 3

The American Gastroenterological Association recommends that clinicians should not wait for specific lab abnormalities to prescribe Creon if clinical symptoms of EPI are present, as the diagnosis of EPI requiring treatment is primarily clinical 1, 2